A81 POOLED SAFETY ANALYSIS FROM THE USTEKINUMAB CROHN’S DISEASE AND PSORIATIC DISEASES PHASE 2 AND 3...
A81 POOLED SAFETY ANALYSIS FROM THE USTEKINUMAB CROHN’S DISEASE AND PSORIATIC DISEASES PHASE 2 AND 3 TRIALS
About this item
Full title
Author / Creator
Feagan, B G , Sands, B E , de Villiers, W , Ott, E , Gasink, C , Lang, Y , Szapary, P , Jacobstein, D and Ghosh, S
Publisher
US: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
US: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Abstract
Background
Ustekinumab (UST) is well-established in psoriasis (PsO) & psoriatic arthritis (PsA) with up to 5 years safety data from psoriasis clinical trials with 3117 pts & 8998 patient years (PY). However, limited safety data have been presented in Crohn’s disease (CD). In CD, Phase 2/3 data show that UST is safe & effective.
Ai...
Alternative Titles
Full title
A81 POOLED SAFETY ANALYSIS FROM THE USTEKINUMAB CROHN’S DISEASE AND PSORIATIC DISEASES PHASE 2 AND 3 TRIALS
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6507608
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6507608
Other Identifiers
ISSN
2515-2084
E-ISSN
2515-2092
DOI
10.1093/jcag/gwy008.082
